Logo image of FBIOP

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Fundamental Analysis

NASDAQ:FBIOP - Nasdaq - US34960Q2084 - Currency: USD

7.88  +0.73 (+10.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FBIOP. FBIOP was compared to 551 industry peers in the Biotechnology industry. FBIOP may be in some trouble as it scores bad on both profitability and health. FBIOP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FBIOP has reported negative net income.
FBIOP had a negative operating cash flow in the past year.
In the past 5 years FBIOP always reported negative net income.
FBIOP had a negative operating cash flow in each of the past 5 years.
FBIOP Yearly Net Income VS EBIT VS OCF VS FCFFBIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

FBIOP has a Return On Assets of -28.50%. This is in the better half of the industry: FBIOP outperforms 68.12% of its industry peers.
FBIOP has a worse Return On Equity (-228.07%) than 69.75% of its industry peers.
Industry RankSector Rank
ROA -28.5%
ROE -228.07%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIOP Yearly ROA, ROE, ROICFBIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

With an excellent Gross Margin value of 67.37%, FBIOP belongs to the best of the industry, outperforming 80.62% of the companies in the same industry.
FBIOP's Gross Margin has declined in the last couple of years.
FBIOP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIOP Yearly Profit, Operating, Gross MarginsFBIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FBIOP has more shares outstanding
Compared to 5 years ago, FBIOP has more shares outstanding
The debt/assets ratio for FBIOP is higher compared to a year ago.
FBIOP Yearly Shares OutstandingFBIOP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIOP Yearly Total Debt VS Total AssetsFBIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.12, we must say that FBIOP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.12, FBIOP is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
FBIOP has a Debt/Equity ratio of 2.53. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.53, FBIOP is not doing good in the industry: 81.88% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Altman-Z -6.12
ROIC/WACCN/A
WACC10.63%
FBIOP Yearly LT Debt VS Equity VS FCFFBIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

FBIOP has a Current Ratio of 1.72. This is a normal value and indicates that FBIOP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.72, FBIOP is doing worse than 79.53% of the companies in the same industry.
A Quick Ratio of 1.55 indicates that FBIOP should not have too much problems paying its short term obligations.
FBIOP has a worse Quick ratio (1.55) than 79.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.55
FBIOP Yearly Current Assets VS Current LiabilitesFBIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

FBIOP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.29%, which is quite impressive.
Looking at the last year, FBIOP shows a very negative growth in Revenue. The Revenue has decreased by -32.11% in the last year.
Measured over the past years, FBIOP shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.
EPS 1Y (TTM)60.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
Revenue 1Y (TTM)-32.11%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%0.84%

3.2 Future

The Earnings Per Share is expected to grow by 22.90% on average over the next years. This is a very strong growth
FBIOP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.44% yearly.
EPS Next Y56.33%
EPS Next 2Y32.01%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue Next Year45.64%
Revenue Next 2Y45.19%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIOP Yearly Revenue VS EstimatesFBIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIOP Yearly EPS VS EstimatesFBIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.
Also next year FBIOP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIOP Price Earnings VS Forward Price EarningsFBIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIOP Per share dataFBIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

FBIOP's earnings are expected to grow with 22.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.01%
EPS Next 3Y22.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBIOP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (8/15/2025, 8:18:30 PM)

7.88

+0.73 (+10.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners13.05%
Inst Owner ChangeN/A
Ins Owners15%
Ins Owner ChangeN/A
Market Cap233.01M
Analysts82.5
Price Target60.25 (664.59%)
Short Float %0.01%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-5.3%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.66%
Min EPS beat(2)2.39%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)5.9%
Min EPS beat(4)-25.23%
Max EPS beat(4)41.5%
EPS beat(8)6
Avg EPS beat(8)21.16%
EPS beat(12)7
Avg EPS beat(12)11.16%
EPS beat(16)8
Avg EPS beat(16)-21.02%
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-9.04%
Max Revenue beat(2)10.85%
Revenue beat(4)1
Avg Revenue beat(4)-13.7%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)10.85%
Revenue beat(8)4
Avg Revenue beat(8)13.76%
Revenue beat(12)4
Avg Revenue beat(12)0.89%
Revenue beat(16)7
Avg Revenue beat(16)-0.47%
PT rev (1m)-12.84%
PT rev (3m)3.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.1%
EPS NY rev (1m)0%
EPS NY rev (3m)12.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.03
P/FCF N/A
P/OCF N/A
P/B 10.47
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.72
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-3.02
FCFYN/A
OCF(TTM)-2.51
OCFYN/A
SpS1.95
BVpS0.75
TBVpS-0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.5%
ROE -228.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.37%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.55
Altman-Z -6.12
F-Score3
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
EPS Next Y56.33%
EPS Next 2Y32.01%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-32.11%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%0.84%
Revenue Next Year45.64%
Revenue Next 2Y45.19%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%
EBIT growth 1Y17.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.35%
EBIT Next 3Y22.94%
EBIT Next 5YN/A
FCF growth 1Y49.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.69%
OCF growth 3YN/A
OCF growth 5YN/A